Mallinckrodt Completes Sale Of Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million

Mallinckrodt plc (NYSE:  MNK), a leading specialty pharmaceutical company, announced that it has closed the sale of its global Nuclear Imaging business to IBA Molecular (IBAM) for approximately $690 million before tax, including up-front and contingent considerations and the assumption of long-term obligations.

Mallinckrodt's Nuclear Imaging operations encompass two manufacturing facilities and a total of more than 800 employees in locations across the globe, including nearly 350 in the St. Louis, Mo. area. The entire workforce and the manufacturing facilities have been transferred to IBAM.

Mallinckrodt's action to divest Nuclear Imaging continues the company's strategy to transform its portfolio with specialty pharmaceutical assets that are durable, innovative and have significant volume growth potential. 

To read more please visit http://www.prnewswire.com/news-releases/mallinckrodt-completes-sale-of-its-nuclear-imaging-business-to-iba-molecular-for-approximately-690-million-300398172.html

Source: PR Newswire Association LLC